Search results
153 Results for 'Harvard Medical School'
- Technologies (20)
- Collaborations (0)
- Team (0)
- News (114)
- Pages (0)
- Multimedia (18)
- Publications (0)
- Jobs (0)
- Events (1)
Technologies 20
-
GC Therapeutics: Changing the Future of Cell Therapies
GC Therapeutics (GCTx) is applying their stem cell-engineering TFome platform to overcome barriers in the development and manufacturing of cell therapies to improve patient access across a broad range of disease areas. -
DNA Nanoswitch Calipers for Single-Molecule Proteomics
DNA nanoswitch calipers are a first-of-their-kind research tool that leverage DNA’s unique molecular qualities to study post-translational modifications on proteins to unlock a new frontier of medicine. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
Ichor: Reversing Aging
Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health. -
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers. -
DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions.
News 114
Multimedia 18
-
Video/Animation20-ish Questions with Pamela Silver20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Pamela Silver, a Founding Core Faculty member of the Wyss Institute as well as the Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology at... -
Video/Animation20-ish Questions with George Church20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows George Church, a founding Core Faculty member of the Wyss Institute and lead of the Synthetic Biology Focus Area. Credit: Wyss Institute at Harvard University -
Video/AnimationAminoX: Making Better Protein Drugs, Quicker and CheaperA synthetic biology and advanced chemistry platform that efficiently incorporates non-standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University -
Video/AnimationEnhancing Lactation to Improve Infant and Maternal HealthLactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions. Credit: Wyss Institute at Harvard University -
Audio/PodcastReimagining Infertility – An Interview with Christian KrammeChristian Kramme imagines a world where all people can have a child on their own time frame. Such “reproductive autonomy” is not the case today – infertility is a growing problem worldwide, and existing treatments like IVF are incredibly taxing on women’s bodies and too expensive for most of the global population to access. Listen... -
Video/AnimationLight-Seq: Light-Directed In Situ Barcoding of BiomoleculesThis animation explains how the Light-Seq technology works to barcode and deep-sequence selected cell populations in tissue samples, and how the team applied it to the analysis of distinct and rare cells in the mouse retina. Credit: Wyss Institute at Harvard University.
